Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001238244 | SCV001411043 | likely benign | Alagille syndrome due to a JAG1 point mutation | 2023-06-16 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004629513 | SCV005127499 | uncertain significance | Cardiovascular phenotype | 2024-05-23 | criteria provided, single submitter | clinical testing | The p.T1189M variant (also known as c.3566C>T), located in coding exon 26 of the JAG1 gene, results from a C to T substitution at nucleotide position 3566. The threonine at codon 1189 is replaced by methionine, an amino acid with similar properties. This amino acid position is conserved. In addition, this alteration is predicted to be tolerated by in silico analysis. Based on the available evidence, the clinical significance of this variant remains unclear. |
Prevention |
RCV004740624 | SCV005351149 | uncertain significance | JAG1-related disorder | 2024-07-12 | no assertion criteria provided | clinical testing | The JAG1 c.3566C>T variant is predicted to result in the amino acid substitution p.Thr1189Met. To our knowledge, this variant has not been reported in the literature. This variant is reported in 0.00088% of alleles in individuals of European (Non-Finnish) descent in gnomAD. At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |